# MANKIND (MANKIND) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/mankind

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,315.4
- Change: +0.67%
- As of: 2026-09-18
- 1D return: +0.03%
- 5D return: +2.78%
- 1M return: -3.53%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Mankind is trading at ₹2300.7, with a mixed technical stance across timeframes. Daily and monthly indicators suggest a bearish trend, with the price below key moving averages and the Supertrend indicator. However, the weekly timeframe shows a bullish Supertrend direction, although the price is below its 20-day and 50-day Exponential Moving Averages (EMAs). Recent patterns include an active Inside Bar on the weekly chart and a Doji on the daily chart as of September 18, 2026. The stock has experienced a recent downward price move with elevated volume on September 16, 2026.

The nearest support level is observed at ₹2283.63, approximately 0.74% below the current price. Resistance is noted at ₹2325.17, about 1.06% above the current price. The stock's risk profile includes an annualized volatility of 28% and a current drawdown of -22%. The Average True Range (ATR) as a percentage of the price is 2.25%.

Key conditions to monitor include the price's ability to move decisively above the ₹2325.17 resistance level, which could signal a shift in the short-term trend. Conversely, a break below the ₹2283.63 support level, especially with increased volume, may indicate further downside pressure. The divergence between the weekly bullish Supertrend and the daily/monthly bearish signals warrants close observation for trend confirmation.

- Current price as of September 18, 2026: ₹2300.7
- Nearest support level: ₹2283.63 (approx. 0.74% below current price)
- Nearest resistance level: ₹2325.17 (approx. 1.06% above current price)
- Active patterns as of September 18, 2026: Weekly Inside Bar, Daily Doji
- Recent anomaly: Downward price move with volume increase on September 16, 2026

- Inside Bar
- Doji
- Outside Bar
- Bearish Engulfing Reversal
- Evening Star
- Bullish Engulfing Reversal

### News Context

In the week ending September 18, 2026, Mankind Pharma was highlighted by market commentators. On September 16, 2026, Ganesh Dongre, Senior Manager - Technical, identified Mankind Pharma as a top stock recommendation for September 16, 2026. This occurred amidst broader market fluctuations, with the Sensex and Nifty experiencing declines on September 16, 2026, influenced by rising crude oil prices and inflation concerns. The pharmaceutical sector, however, saw a positive turn on September 17, 2026, snapping a five-day losing streak, though overall market sentiment remained cautious due to indications of further rate hikes by the US Federal Reserve.

- On September 16, 2026, Ganesh Dongre, Senior Manager - Technical, recommended Mankind Pharma as a top stock pick.
- The Indian stock market, including the Sensex and Nifty 50, experienced a decline on September 16, 2026.
- Pharma shares snapped a five-day losing streak on September 17, 2026.

- Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Top stocks to buy today: Stock recommendations for September 16, 2026 - check list
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Seven stocks to buy

### What Changed

Mankind Pharma's recent filings on September 17, 2026, indicate shareholder approval for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. This appointment, effective August 10, 2026, was passed with a significant majority of 99.9627% of votes polled during a remote e-voting period that concluded on September 17, 2026. Separately, a news report from Mint on an unspecified recent date discusses potential changes to rules regarding the sale of medical devices like pulse oximeters and glucometers in grocery stores, aimed at reducing compliance for low-risk products. The company's share price saw a marginal increase from ₹2300.0 to ₹2300.7 between the observation date of September 18, 2026, and its previous trading day.

- Shareholders approved Mr. Anish Vanraj Bafna's appointment as Non-Executive Independent Director via postal ballot, with voting results submitted on September 17, 2026.
- The resolution for Mr. Bafna's appointment received 99.9627% approval from votes polled, with the e-voting period ending September 17, 2026.
- A news report indicates potential government plans to change rules for selling low-risk medical devices in grocery stores.
- Mankind Pharma's stock price closed at ₹2300.7 on September 18, 2026, a slight increase from its previous closing price of ₹2300.0.

- Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint
- Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting

### Official Filings

Mankind Pharma Limited has disclosed several key developments. On August 26, 2026, the Board of Directors approved the voluntary liquidation of its wholly owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), with the intention to integrate BSVL's business into the parent company. This integration is planned on a going concern basis, and the minority shareholder in BSVL will receive cash equivalent to 4% of BSVL's fair value. This move was further approved by BSVL's members on September 7, 2026, subject to creditor approval under the Insolvency and Bankruptcy Code. Additionally, on September 1, 2026, the company allotted 49,112 equity shares under its Employee Stock Option Plan (ESOP), increasing its paid-up share capital. In terms of governance, shareholders approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a five-year term starting August 10, 2026, with a significant majority of 99.9627% of votes in favor. The company also announced its participation in several investor meetings scheduled for mid-September 2026, including the Jefferies 5th India Forum, a Health Care Forum, and the J.P. Morgan India Conference.

- On August 26, 2026, the Board approved the voluntary liquidation of subsidiary Bharat Serums and Vaccines Limited (BSVL) for business integration.
- Shareholders of BSVL approved the voluntary liquidation on September 7, 2026, pending creditor approval.
- On September 1, 2026, 49,112 equity shares were allotted under ESOP, increasing paid-up capital.
- Shareholders approved Mr. Anish Vanraj Bafna's appointment as Non-Executive Independent Director on September 17, 2026, with 99.9627% of votes in favor.
- The company is scheduled to participate in investor meetings from September 17 to September 21, 2026.

- Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Mankind Pharma Limited has informed the Exchange about ESG Rating |SUBJECT: General Updates
- Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- MANKIND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Update on Voluntary Liquidation of Bharat Serums and Vaccines Limited, a WOS. |SUBJECT: General Updates
- Mankind Pharma Limited has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL
- Mankind Pharma Limited has informed the Exchange regarding Allotment of 49112 Shares. |SUBJECT: ESOP/ESOS/ESPS
- Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation. |SUBJECT: Other Restructuring
- Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation. |SUBJECT: Outcome of Board Meeting
- Mankind Pharma Limited has informed the Exchange regarding Other Restructuring |SUBJECT: Other Restructuring-XBRL

### Fundamentals

Mankind Pharma reported revenue from operations of ₹4,030.59 crore for Q1 FY2026-27. This represents a sequential increase from ₹3,442.93 crore in Q4 FY2025-26 and ₹3,567.20 crore in Q3 FY2025-26. Profit Before Exceptional Items And Tax also saw an upward trend, reaching ₹765.51 crore in Q1 FY2026-27, compared to ₹679.34 crore in Q4 FY2025-26 and ₹612.38 crore in Q3 FY2025-26. Profit Loss For Period followed a similar pattern, increasing to ₹574.09 crore in Q1 FY2026-27 from ₹559.42 crore in Q4 FY2025-26 and ₹413.88 crore in Q3 FY2025-26. Finance costs have shown a decrease over the periods, from ₹157.20 crore in Q3 FY2025-26 to ₹109.98 crore in Q1 FY2026-27. Other Expenses, however, increased to ₹962.63 crore in Q1 FY2026-27 from ₹803.08 crore in Q4 FY2025-26.

- Revenue from operations for Q1 FY2026-27 was ₹4,030.59 crore.
- Profit Before Exceptional Items And Tax for Q1 FY2026-27 stood at ₹765.51 crore.
- Profit Loss For Period in Q1 FY2026-27 was ₹574.09 crore.
- Finance Costs decreased to ₹109.98 crore in Q1 FY2026-27.
- Other Expenses increased to ₹962.63 crore in Q1 FY2026-27.

### Bull Case

The company's stock has shown positive returns over the last six months, with a return of 0.09. Additionally, the weekly trend analysis indicates a bullish Supertrend direction as of September 18, 2026. While the daily and monthly trends show a bearish Supertrend direction, the weekly trend suggests potential upward momentum. The stock is currently trading above its 200-day Simple Moving Average (SMA) of ₹2281.97, indicating a longer-term positive price trend. There is also a noted support level at ₹2283.63.

- The stock generated a return of 0.09 in the six months leading up to September 18, 2026.
- As of September 18, 2026, the weekly trend analysis shows a bullish Supertrend direction.
- The stock's closing price of ₹2300.7 on September 18, 2026, is above the 200-day SMA of ₹2281.97.
- A support level is identified at ₹2283.63.

- Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Top stocks to buy today: Stock recommendations for September 16, 2026 - check list
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Seven stocks to buy

### Bear Case

The company's stock is currently trading below key moving averages, with the 20-day Exponential Moving Average (EMA) at ₹2328.97 and the 50-day EMA at ₹2380.59, both above the current close of ₹2300.7. The daily trend indicator, Supertrend, is also showing a bearish signal. Over the past year, the stock has experienced a decline of 13%, and since its inception, it has seen a 20% decrease. The current drawdown stands at 22%, with a maximum drawdown recorded at 34%, indicating significant past price depreciation. Additionally, the stock's annualized volatility is 28%, suggesting a higher degree of price fluctuation.

- As of September 18, 2026, the stock's daily Supertrend indicator is in a bearish direction.
- The stock has experienced a 13% decrease in value over the past year.
- The current drawdown for the stock is 22%, with a maximum drawdown of 34% observed.
- The 20-day EMA (₹2328.97) and 50-day EMA (₹2380.59) are both above the current closing price of ₹2300.7 as of September 18, 2026.

- Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Top stocks to buy today: Stock recommendations for September 16, 2026 - check list
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Seven stocks to buy

### FAQs

**What was the outcome of Mankind Pharma's recent shareholder vote on director appointments?**

On September 17, 2026, Mankind Pharma Limited announced that shareholders approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a five-year term starting August 10, 2026. The approval was based on remote e-voting, which concluded on September 17, 2026. The resolution received 99.9627% of the votes polled in favor, with 396,056,973 votes in favor and 147,811 votes against.

**What recent investor engagement activities has Mankind Pharma undertaken?**

Mankind Pharma's management was scheduled to participate in investor meetings in mid-September 2026. These included the Jefferies 5th India Forum in Gurgaon on September 17, 2026, the Health Care Forum in Mumbai on September 18, 2026, and the J.P. Morgan India Conference in Mumbai on September 21, 2026. These events involved one-on-one or group meetings with analysts and institutional investors.

**What is the current technical trend and key price levels for Mankind Pharma?**

As of September 18, 2026, the daily trend for Mankind Pharma indicates a bearish SuperTrend direction with a value of 2401.69. The closing price was ₹2300.7. Key support levels are identified at ₹2283.63 and ₹2274.07, while resistance levels are noted at ₹2325.17 and ₹2350.33.

**What corporate actions has Mankind Pharma's wholly owned subsidiary, BSVL, taken?**

On September 7, 2026, members of Bharat Serums and Vaccines Limited (BSVL), a wholly owned subsidiary of Mankind Pharma Limited, approved the voluntary liquidation of BSVL. This decision is subject to creditor approval under the Insolvency and Bankruptcy Code, 2016.

- Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Top stocks to buy today: Stock recommendations for September 16, 2026 - check list
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Seven stocks to buy
- Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Mankind Pharma Limited has informed the Exchange about ESG Rating |SUBJECT: General Updates
- Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- MANKIND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Update on Voluntary Liquidation of Bharat Serums and Vaccines Limited, a WOS. |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Moderate Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹2,283.63
- Risk regime: Price Risk Requires Attention

### Support levels
- 2274.073046875
- 2214.478125
- 2150.6

### Resistance levels
- 2441.4265625
- 2496.8
- 2570.8

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.03% |
| return_10 | -2.87% |
| return_1m | -3.33% |
| return_1y | -12.80% |
| return_20 | -3.53% |
| return_3m | -4.38% |
| return_5 | +2.78% |
| return_6m | +9.40% |
| return_since_start | -20.14% |
| return_ytd | +6.29% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -34.39% |
| annualized_volatility | +28.15% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Pre-Tax Profit Rise, but Higher Tax Expense Moderates Net Profit Growth

Mankind Pharma reported higher revenue and a sharp increase in profit before tax during the first quarter of FY2026‑27. The improvement in pre‑tax earnings was helped by a substantial drop in finance costs. However, a much larger tax expense limited the rise in net profit, which grew moderately from a year earlier and only slightly from the previous quarter.

## Revenue and Profit Before Tax

Revenue from operations was ₹4,030.59 crore in Q1 FY2026‑27, compared with ₹3,570.35 crore in the same quarter last year and ₹3,442.93 crore in the preceding quarter. The year‑on‑year growth was 12.9%, while the sequential increase of 17.1% followed three quarters of declining revenue.

Profit before tax (PBT) rose to ₹765.51 crore, up 42.5% from ₹537.32 crore a year earlier and 16.7% from ₹656.18 crore in the previous quarter. As a percentage of revenue, PBT improved from 15.0% in Q1 FY2025‑26 to 19.0% in the current quarter, meaning revenue grew faster than total costs before tax.

## Finance Costs and Other Expenses

Finance costs fell to ₹109.98 crore, a decline of 35.6% year‑on‑year from ₹170.65 crore and 22.4% sequentially from ₹141.75 crore. This reduction contributed directly to the higher pre‑tax profit.

Other expenses increased to ₹962.63 crore from ₹886.58 crore a year earlier, a rise of 8.6%. As a share of revenue, other expenses declined from 24.8% to 23.9%, so these costs grew at a slower pace than revenue.

## Tax Expense and Net Profit

The tax expense was ₹195.36 crore, up from ₹95.87 crore a year earlier and ₹99.75 crore in the previous quarter. The effective tax rate moved from 17.8% in Q1 FY2025‑26 to 25.5% in the current quarter.

Net profit (profit for the period) came in at ₹574.09 crore, 29.1% higher than the ₹444.62 crore posted a year ago but only 2.6% above the ₹559.42 crore recorded in the preceding quarter. The large increase in the tax expense absorbed much of the pre‑tax profit growth, holding the sequential net profit rise to a small amount.

## Earnings Per Share and Comprehensive Income

Basic earnings per share were ₹13.76, up from ₹10.62 a year earlier and from ₹13.44 sequentially. Diluted earnings per share showed a similar pattern.

Comprehensive income for the period was ₹553.78 crore, up 24.8% year‑on‑year from ₹443.86 crore but down 5.9% sequentially from ₹588.36 crore. The sequential decline in comprehensive income, while net profit rose, indicates that other comprehensive income was negative in the quarter.

## Key Takeaway

Mankind Pharma’s revenue increased, and pre‑tax profit grew sharply with the help of lower finance costs. However, a significantly higher tax expense reduced the amount of that gain that reached the bottom line. Net profit rose year‑on‑year but showed only a modest sequential increase as the effective tax rate moved from 17.8% to 25.5%.

### Ratios

## Official filings

- 2026-09-17 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_17092026190722_Covering_SD.pdf)
- 2026-09-15 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_15092026195248_ESGRatings.pdf)
- 2026-09-11 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_11092026144121_Intimationconference.pdf)
- 2026-09-11 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20260911_145222610.xml)
- 2026-09-07 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_07092026171041_DisclosureSD.pdf)
- 2026-09-01 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_21117_WebXMLFile_20260901_175450538.xml)
- 2026-09-01 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_01092026180216_ESOP_Allotment_01092026.pdf)
- 2026-08-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26082026164439_Outcome_26082026_sd.pdf)
- 2026-08-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_26082026163943_Outcome_26082026_sd.pdf)
- 2026-08-26 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_21117_WebXMLFile_20260826_164916716.xml)
- 2026-08-20 — Press Release: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_20082026133735_Covering_SD.pdf)
- 2026-08-19 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_19082026102533_Covering_sd.pdf)
- 2026-08-18 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_18082026155056_CoverPB.pdf)
- 2026-08-18 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_21117_WebXMLFile_20260818_160808191.xml)
- 2026-08-17 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_17082026230916_Intimation_to_Stk_Exchnage_for_release_of_pledge.pdf)
- 2026-08-13 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_21117_WebXMLFile_20260813_214424640.xml)
- 2026-08-13 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_21117_WebXMLFile_20260813_213701219.xml)
- 2026-08-13 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_13082026213112_Intimationsd.pdf)
- 2026-08-10 — Management Change: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_10082026161543_Outcome_SD.pdf)
- 2026-08-10 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_10082026124202_Intimation_IC.pdf)
- 2026-08-10 — Management Change: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_21117_WebXMLFile_20260810_163407810.xml)
- 2026-08-10 — Management Change: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_10082026161255_Outcome_SD.pdf)
- 2026-08-10 — Generic Announcement: Mankind Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_21117_WebXMLFile_20260810_164040526.xml)
- 2026-08-06 — Generic Announcement: Mankind Pharma Limited held its 35th Annual General Meeting on August 4, 2026, via video conferencing. All four resolutions presented, including the adoption of financial statements for the year ended March 31, 2026, the re-appointment of Mr. Rajeev Juneja as Director, the re-appointment of Mr. Satish Kumar Sharma as Whole-time Director, and the ratification of cost auditors' remuneration for FY 2026-27, were passed with the requisite majority. The voting results and the consolidated scrutinizer's report were filed on August 6, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_06082026160049_Cover_SD.pdf)
- 2026-08-04 — Generic Announcement: Mankind Pharma Limited held its Thirty-Fifth Annual General Meeting on August 4, 2026, via video conference. The meeting included the adoption of standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of a director retiring by rotation, the approval of Satish Kumar Sharma as Whole-time Director, and the ratification of cost auditors' remuneration for FY 2026-27. The results of the e-voting on these resolutions will be filed with stock exchanges and posted on the company website. — [Official attachment](https://nsearchives.nseindia.com/corporate/MANKIND1_04082026173214_Proceedings.pdf)

## News and market events

- 2026-09-18 — Mint: **Pulse oximeters, glucometers at grocery stores? Centre plans rule change | Mint** — The move is aimed at reducing compliance requirements for low-risk products that health authorities want to make more widely available. — [Source](https://www.livemint.com/industry/pulse-oximeters-pregnancy-kits-bp-monitoring-machines-retail-sales-india-11789668774172.html)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-16 — Times of India: **Top stocks to buy today: Stock recommendations for September 16, 2026 - check list** — India Business News: Stock market recommendations: PN Gadgil Jewellers, Mankind Pharma, and BEML are the top stocks recommended by Ganesh Dongre, Senior Manager - Technica. — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-september-16-2026-pn-gadgil-jewellers-mankind-pharma-beml-best-stocks-to-buy-today/articleshow/134277458.cms)
- 2026-09-16 — Mint: **Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Seven stocks to buy** — The Indian stock market is set for a flat opening on 16 September, following a decline in global markets. The Sensex fell 777.94 points, while the Nifty 50 dropped 279.50 points, influenced by rising crude oil prices and inflation concerns amid geopolitical tensions. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-trade-guide-for-sensex-nifty-50-crude-oil-and-gold-seven-stocks-to-buy-11789520520389.html)
- 2026-09-10 — Mint: **Govt plans central licensing for all sterile drugs after quality lapses | Today News** — The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally. — [Source](https://www.livemint.com/news/govt-plans-central-licensing-for-all-sterile-drugs-after-240-injection-samples-fail-quality-tests-medicine-11789033517269.html)
- 2026-09-09 — BUSINESS: **Mankind Pharma Ltd drops for fifth straight session** — Mankind Pharma Ltd is quoting at Rs 2280.2, down 1.25% on the day as on 13:19 IST on the NSE. The stock tumbled 12.59% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/mankind-pharma-ltd-drops-for-fifth-straight-session-126090900780_1.html)
- 2026-09-08 — Economic Times: **Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake** — Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/tata-capital-healthcare-fund-to-exit-linux-laboratories-as-chryscapital-buys-20-25-stake/articleshow/133939441.cms)
- 2026-09-01 — Economic Times: **Stocks in news: Bharti Airtel, Happiest Minds Technologies, PVR INOX, Milky Mist Dairy and Mankind Pharma** — Indian equity markets ended lower on August 31, responding to prevailing global economic dynamics. A modest decline in the Nifty50 index brought it below essential moving averages. Key corporate updates emerged, including major merger announcements and buyback initiatives from Happiest Minds Technologies and PVR INOX. Milky Mist Dairy showed remarkable profit growth, whereas E2E Networks secured a vital contract. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-happiest-minds-technologies-pvr-inox-milky-mist-dairy-and-mankind-pharma/articleshow/133658328.cms)
- 2026-08-31 — Economic Times: **Mankind Pharma divests entire stake in Broadway Hospitality to AKRK Projects** — Mankind Pharma has completed the sale of its entire stake in Broadway Hospitality Services. The transaction involved transferring 100 percent ownership to AKRK Projects LLP and its partners. This divestment officially concluded on August 31, 2026, as per the company's filing. Broadway Hospitality Services is no longer a wholly-owned subsidiary of Mankind Pharma. The total consideration for this divestment was reported as Rs 49 crore. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-divests-entire-stake-in-broadway-hospitality-to-akrk-projects/articleshow/133658877.cms)
- 2026-08-20 — FREEPRESSJOURNAL.IN: **Mankind Pharma Licenses Two Insulin Products, Expands Diabetes Portfolio** — Mankind Pharma signs an exclusive India licensing deal for two insulin products, expanding its injectable diabetes portfolio and access to advanced treatments. — [Source](https://www.freepressjournal.in/business/mankind-pharma-licenses-two-insulin-products-expands-diabetes-portfolio)
- 2026-08-20 — CNBC-TV18: **Mankind Pharma inks exclusive deal for two insulin analogues in India** — Mankind Pharma has entered an exclusive in-licensing and marketing agreement with China’s Chongqing Chenan Biopharmaceutical to commercialise two insulin analogues in India, expanding its injectable diabetes portfolio as the company builds on recent growth. — [Source](https://www.cnbctv18.com/market/mankind-pharma-inks-exclusive-deal-for-two-insulin-analogues-in-india-19973613.htm)
- 2026-07-31 — Mint: **Top Gainers & Losers on 31 July: Bajaj Finance, Hyundai Motor, GAIL, Tata Motors, Redington among top gainers today** — Indian equities closed the last trading day of July with modest gains, driven by financial and auto stocks. The Nifty 50 rose 0.20% to 24,336, while Sensex advanced 0.21% to 78,091, reflecting positive market trends despite concerns over crude oil prices. — [Source](https://www.livemint.com/market/stock-market-news/top-gainers-losers-on-31-july-bajaj-finance-hyundai-motor-gail-tata-motors-redington-among-top-gainers-today-11785490241096.html)
- 2026-07-31 — CNBC-TV18: **Nifty 500 today: From Auto, pharma, defence to chemical, these are the biggest movers so far** — These are the top Nifty 500 movers today, spanning sectors from auto and financial services to chemicals, telecom, defence electronics, and pharma in the first hour of the last day this week's trade. Check who they are: — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-hyundai-netweb-bajaj-finance-thermax-hfcl-mankind-pharma-19958532.htm)
- 2026-07-30 — Mint: **Domestic focus powers Torrent, Mankind in June quarter | Company Business News** — India-focused drugmakers outpaced US-facing peers as strong domestic demand and acquisitions drove double-digit June-quarter growth. — [Source](https://www.livemint.com/companies/company-results/domestic-focus-powers-torrent-mankind-in-june-quarter-medicine-pharma-merger-growth-acquisition-11785423266899.html)
- 2026-07-30 — CNBC-TV18: **Mankind Pharma Q1 profit rises 30%, margins expand on strong domestic business** — Mankind Pharma reported a 30% year-on-year rise in first-quarter net profit, driven by steady revenue growth and improved operating margins, as strong performance in its domestic chronic business and a rebound in acute therapies offset slower growth in consumer healthcare. — [Source](https://www.cnbctv18.com/market/earnings/mankind-pharma-q1-profit-rises-30-margins-expand-on-strong-domestic-business-19957966.htm)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: Hyundai Motor India profit falls 35%, Mankind Pharma margin rises** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)
- 2026-07-30 — CNBC-TV18: **Market close | Stock Market Highlights: Late buying lifts Sensex 273 pts, Nifty settles above 24,300; auto stocks shine** — Sensex Today | Stock Market LIVE Updates: Today is the monthly expiry of the Sensex contracts. 24,000 on the downside is key for the Nifty, while the July 17 high of 24,367 is the first hurdle to cross on the upside — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-expiry-infosys-it-eicher-dabur-vedanta-irfc-asian-paints-share-price-liveblog-19957305.htm)
- 2026-07-30 — Mint: **Stocks to watch: Swiggy, IRFC, Bajaj Housing Finance among shares in focus today; check list here** — Stock market today: Gift Nifty was trading near the 24,330 mark, up over 19 points from the previous close of Nifty futures. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-watch-swiggy-irfc-bajaj-housing-finance-among-shares-in-focus-today-check-list-here-11785376791464.html)
- 2026-07-27 — Economic Times: **US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipeline** — Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw significant drops in their net profits and operating margins. However, their domestic businesses continued to perform well, offering a positive outlook. Obesity therapies and specialty product launches are expected to drive future growth for these companies. Analysts have consequently reduced earnings forecasts for the upcoming fiscal years. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/us-market-drag-keeps-dr-reddys-cipla-under-pressure-despite-strong-product-pipeline/articleshow/132650538.cms)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)
- 2026-07-22 — Economic Times: **Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028** — Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption before imposing steep duties from 2028. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/sun-pharma-cipla-other-pharma-stocks-in-focus-as-trump-unveils-100-200-tariffs-on-generic-drugs-from-2028/articleshow/132550249.cms)
- 2026-07-20 — Mint: **Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street** — Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each. — [Source](https://www.livemint.com/market/stock-market-news/cipla-ajanta-pharma-to-alkem-laboratories-pharma-stocks-rise-amid-weak-trends-on-dalal-street-11784531087488.html)
- 2026-07-15 — Mint: **Market strategy: Kotak Equities adds TCS, SBI Life Insurance in model portfolio, raises weight on L&T** — Market strategy: Both TCS and SBI Life have been assigned a weight of 150 basis points (bps) in the brokerage’s model portfolio. The brokerage, however, clarified that TCS's inclusion in the model portfolio should not be interpreted as a broader endorsement of the IT services sector. — [Source](https://www.livemint.com/market/stock-market-news/market-strategy-kotak-equities-adds-tcs-sbi-life-insurance-in-model-portfolio-raises-weight-on-l-and-t-11784106568903.html)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical and healthcare products.

### Business segments
- **Pharmaceutical Formulations:** This segment addresses both acute and chronic therapeutic areas, offering formulations for conditions such as anti-infectives, cardiovascular diseases, gastrointestinal disorders, anti-diabetic treatments, dermatological issues, erectile dysfunction, and anti-allergic treatments.
- **Consumer Healthcare Products:** The company also has a significant presence in the consumer healthcare products market, focusing on manufacturing, packaging, and marketing these products.

### Competitive strengths
- Diverse product portfolio across multiple therapeutic areas.
- Extensive manufacturing, packaging, and marketing capabilities.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/mankind
Markdown representation: https://faxioms.com/stocks/mankind?render=md